AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11228385
Drug: Pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent vaccine (DTP-Hib-HB) plus placebo (Group A, n=619)
Trial: 11228385
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine (DTP-HB) plus Hib vaccine (Group B, n=620)
Trial: 11228385
Drug: Bivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent vaccine (Hib-HB) plus DTP (Group C, n=226)
Trial: 11228385
Drug: Monovalent hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent hepatitis B vaccine at birth followed by pentavalent vaccine (Group E, n=460)
Trial: 11228385
Drug: Licensed control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed control vaccines (DTP, Hib, HB) (Group D, n=231)
Trial: 9828772
Drug: Metipranolol (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (topical and systemic application)
Trial: 9828772
Drug: Metipranolol (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metipranolol (topical application)
Trial: 6106098
Drug: Diet B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet B (carbohydrate 53%, fibre 54 g)
Trial: 6106098
Drug: Diet A
RxNorm normalized name: Diet Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet A (carbohydrate 53%, fibre 16 g)
Trial: 6106098
Drug: Diet C
RxNorm normalized name: Diet Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet C (carbohydrate 42%, fibre 20 g)
Trial: 27771172
Drug: 250mg resveratrol
RxNorm normalized name: resveratrol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg resveratrol daily for 3 months
Trial: 24297381
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg qw
Trial: 31268376
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg q2w
Trial: 31268376
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg q2w
Trial: 24297381
Drug: Sarilumab ≥150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab ≥150 mg q2w
Trial: 30120894
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (control)
Trial: 23140661
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (100 mg/day)
Trial: 11720400
Drug: Swallowing reflex
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing reflex measured by latent time (LT) for swallowing following bolus injection of distilled water.
Trial: 8326162
Drug: Five-drug combination
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug combination (metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, diazepam)
Trial: 3511346
Drug: Naloxone 2
RxNorm normalized name: naloxone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 2 mg IV
Trial: 28987804
Drug: Revefenacin 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 700 μg
Trial: 28987804
Drug: Ipratropium 500
RxNorm normalized name: ipratropium 500 mcg/2.5 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium 500 μg
Trial: 28987804
Drug: Revefenacin 22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 22 μg
Trial: 26560987
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral sustained release morphine daily for 4 days
Trial: 16086046
Drug: Glutamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (2 g/m²/dose, maximum 4 g, twice daily until 28 days post transplant)
Trial: 11897246
Drug: BCAA 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA 1.5 g
Trial: 11897246
Drug: BCAA 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA 3.0 g
Trial: 11897246
Drug: BCAA 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA 6.0 g
Trial: 11897246
Drug: BCAA (middle-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (middle-dose group)
Trial: 11897246
Drug: BCAA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (1.5 and 3.0 g)
Trial: 10451133
Drug: Femoral 3-in-1
RxNorm normalized name: SUS SCROFA TEMPORAL LOBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral 3-in-1 block with 40 ml ropivacaine 0.2% and 20 ml ropivacaine 0.2% infiltration at the end of surgery
Trial: 7587906
Drug: Chemotherapy protocol
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy protocol without VM-26 and CCNU
Trial: 2112489
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10)
Trial: 110027
Drug: Disodium chromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium chromoglycate (DSCG) nasal spray (2%)
Trial: 23709432
Drug: Nicorandil 12
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 12 mg in 100 mL of 0.9% saline administered intravenously for 30 minutes prior to coronary angiography
Trial: 21849080
Drug: 3-4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 ml/kg BW/h 0.9% saline intravenously for 6 hours
Trial: 21849080
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment consisting of unrestricted oral fluid intake
Trial: 20110017
Drug: Glimepiride 1-mg
RxNorm normalized name: glimepiride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1-mg + Metformin 500-mg combination tablet (test)
Trial: 20110017
Drug: Glimepiride 2-mg
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2-mg + Metformin 500-mg combination tablet (reference)
Trial: 16882276
Drug: Pioglitazone (30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30-45 mg daily for 26 weeks)
Trial: 3046984
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of pectin
Trial: 3046984
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of pectin
Trial: 3046984
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of pectin
Trial: 29505900
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2) plus Carboplatin (AUC 5) every 3 weeks for four cycles (arm A)
Trial: 29505900
Drug: Oral Uracil-Tegafur
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Uracil-Tegafur (UFT) (250 mg/m2) daily for 2 years (arm B)
Trial: 22657157
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg/m(2)/wk and prednisone 1 mg/kg/d (maximum 50 mg) for the first 3 months
Trial: 20491606
Drug: Candesartan-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan-based treatment
Trial: 29734096
Drug: Antidepressants (bupropion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (bupropion, paroxetine) as adjuncts to mood stabilizers
Trial: 29734096
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as adjunct to mood stabilizers
Trial: 25199409
Drug: Diminazene diaceturate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diminazene diaceturate (DA) treatment
Trial: 24319686
Drug: Nilvadipine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (oral administration)
Trial: 20958228
Drug: L-arginine (L-Arg)
RxNorm normalized name: L-Arg
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (L-Arg) supplementation
Trial: 18509120
Drug: Subcutaneous methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous methylnaltrexone (0.15 mg/kg)
Trial: 11232191
Drug: Specific vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific vaccines for hepatitis A and B
Trial: 11232191
Drug: Aggressive combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive combination therapy for chronic hepatitis B and C
Trial: 9081951
Drug: 0.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 ml/kg (1:200,000) epinephrine combined with 0.25% bupivacaine (n = 33)
Trial: 1313098
Drug: Acyclovir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (800 mg orally four times daily for 5 days)
Trial: 2860992
Drug: Atenolol (Tenormin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (Tenormin, 100 mg) given twice daily for 6 weeks
Trial: 30848938
Drug: 4-week multimodal
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week multimodal rehabilitation program (12 intervention sessions and daily home ankle strengthening and stretching)
Trial: 29547070
Drug: Combination HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HIV prevention intervention
Trial: 26845264
Drug: Lithium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium + adjunctive personalized treatment (APT)
Trial: 26845264
Drug: Quetiapine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine + adjunctive personalized treatment (APT)
Trial: 22818869
Drug: Vitamin B(6)
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B(6) (50 mg/d)
Trial: 22818869
Drug: Lysine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine (1 g/d)
Trial: 22818869
Drug: Carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (1 g/d)
Trial: 22818869
Drug: Lysine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine (1 g/d) + Vitamin B(6) (50 mg/d)
Trial: 20631020
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (150,000 IU ergocalciferol, 4 doses over 1 year)
Trial: 12574809
Drug: Melagatran followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melagatran followed by oral ximelagatran (3 mg subcutaneous melagatran started 4-12 h postoperatively, followed by 24 mg oral ximelagatran twice-daily for 8 to 11 days)
Trial: 12574809
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg subcutaneous enoxaparin once-daily, started 12 h preoperatively)
Trial: 1587940
Drug: 1% solution
RxNorm normalized name: GUMSOL 5%-0.01% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% solution of povidon iodine (Betadine)
Trial: 3907910
Drug: Verapamil 20
RxNorm normalized name: verapamil 200 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 20 mg intravenously
Trial: 30773140
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplement with additional micronutrients
Trial: 30773140
Drug: Lipid-based nutritional
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutritional supplement without additional micronutrients
Trial: 20003665
Drug: Cranberry drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry drink (500 ml twice per day)
Trial: 8769051
Drug: GR3219 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR3219 80 mg twice daily
Trial: 1573046
Drug: Alprazolam 6
RxNorm normalized name: Acetylcarnitine/Choline Bitartrate/Cocoa Extract/Gamma Aminobutyric Acid/Ginkgo Biloba Leaf/Glutamic Acid/Grape Seed Extract/Griffonia Seed Extract/Valerian Root Extract/Whey Protein Hydrolysate;Alprazolam 62.5 MG; 0.5 MG Oral Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 6 mg
Trial: 3881905
Drug: Nifedipine in
RxNorm normalized name: nifedipine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine in cold hyperkalemic cardioplegic solution
Trial: 29368365
Drug: Phlorotannin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlorotannin supplement (500 mg/day)
Trial: 26850983
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 μg every 4 hours)
Trial: 26850983
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter (30 mL transcervical)
Trial: 24550378
Drug: Caspofungin preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin preemptive therapy
Trial: 24550378
Drug: Placebo preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preemptive therapy
Trial: 22099607
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (escitalopram)
Trial: 20819537
Drug: Nifekalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant hydrochloride (NIF) administered continuously for at least 12 hours (group L)
Trial: 20819537
Drug: Nifekalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant hydrochloride (NIF) administered for 1 hour (group S)
Trial: 16409566
Drug: Irbesartan, 300
RxNorm normalized name: Irbesartan, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan, 300 mg
Trial: 14978984
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg (intravenous) 8 hourly
Trial: 14978984
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g 8 hourly through a Ryle's tube
Trial: 28520861
Drug: Post-coronary artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-coronary artery bypass grafting medication - Acetylsalicylic acid
Trial: 28520861
Drug: Post-coronary artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-coronary artery bypass grafting medication - Thienopyridine
Trial: 28520861
Drug: Post-coronary artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-coronary artery bypass grafting medication - Statins
Trial: 21301783
Drug: 5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg/kg methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim)
Trial: 21226428
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg (1.5 ml) hyperbaric levobupivacaine 0.5%
Trial: 21226428
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg (4 ml) hypobaric levobupivacaine 0.1875%
Trial: 9481529
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Trial: 9481529
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg elemental phosphate for one week; sodium acid phosphate tablets (500 mg elemental phosphorus) given with meals
Trial: 8570043
Drug: Iodixanol 150
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol 150 mgI/ml
Trial: 8570043
Drug: Iohexol 140
RxNorm normalized name: iohexol 140 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol 140 mgI/ml
Trial: 2096212
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg orally twice daily for 3.5 days
Trial: 81925
Drug: Propranolol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.1 mg/kg intravenously followed by 320 mg orally over 27 h
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 0.49 ng/mL or less
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 0.50-0.99 ng/mL
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 1.00-1.99 ng/mL
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 2.00-2.99 ng/mL
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 3.00-3.99 ng/mL
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 4.00 ng/mL and greater
Trial: 31940039
Drug: Baseline PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PSA level of 2.00 ng/mL or higher
Trial: 28434547
Drug: Stress-dose corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress-dose corticosteroid (SDC) regimen: 2 mg/kg methylprednisolone perioperatively, followed by hydrocortisone infusion (0.2 mg/kg/h) for 5 days
Trial: 25585082
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical diltiazem ointment (for 6 weeks) and botulinum toxin A injection (once)
Trial: 23507282
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg solithromycin orally on day 1, followed by 400 mg orally daily on days 2 to 5
Trial: 23507282
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg levofloxacin orally daily on days 1 to 5
Trial: 19452377
Drug: SSRIs (citalopram,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)
Trial: 11146900
Drug: Propinox 10
RxNorm normalized name: propinox 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propinox 10 mg
Trial: 11146900
Drug: Propinox 20
RxNorm normalized name: propinox 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propinox 20 mg
Trial: 11146900
Drug: Propinox 30
RxNorm normalized name: propinox 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propinox 30 mg
Trial: 3518408
Drug: 5-Aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-Aminosalicylic acid (5-ASA) enema (4-g nightly retention)
Trial: 30242335
Drug: Canakinumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50 mg, 150 mg, or 300 mg) administered subcutaneously every 3 months
Trial: 23418746
Drug: 1-piece (STM)
RxNorm normalized name: STM 217
DrugBank: STM-217 (DB17358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-piece (STM) dental implant system
Trial: 23418746
Drug: 2-piece (BRA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-piece (BRA) dental implant system
Trial: 22592097
Drug: Fosamprenavir (FPV)
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosamprenavir (FPV) with or without ritonavir (100 mg or 200 mg)
Trial: 12693575
Drug: Clue chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clue chemotherapy
Trial: 12693575
Drug: Screen chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screen chemotherapy
Trial: 10091208
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Trial: 10091208
Drug: OCM (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCM (omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h)
Trial: 10091208
Drug: LAC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (lansoprazole 30 mg/12 h, amoxycillin 1 g/12 h, clarithromycin 500 mg/12 h)
Trial: 10091208
Drug: LC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC (lansoprazole 30 mg/12 h, clarithromycin 500 mg/8 h)
Trial: 10091208
Drug: Overall triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall triple therapy
Trial: 7502549
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (Salofalk, 4.5 g/day)
Trial: 7502549
Drug: 6-methylprednisolone (Urbason,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone (Urbason, initial dose 48 mg/day, weekly tapering)
Trial: 2258142
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with interferon antibodies
Trial: 2258142
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without interferon antibodies